Table of contents

  1. Front Matter
    Pages I-XV
  2. Introduction, Chemistry, Receptor Interaction and Platelet Mechanisms

    1. Front Matter
      Pages 1-1
    2. W. Skuballa, B. Radüchel, H. Vorbrüggen
      Pages 17-24
    3. G. de Gaetano, V. Bertelé, C. Cerletti
      Pages 25-37
    4. C.-S. Stürzebecher, W. Losert
      Pages 39-45
    5. E. Tremoli, P. Maderna, L. Mannucci, S. Colli, R. Paoletti
      Pages 47-51
    6. J. MacDermot, U. Alt, P. J. Leigh, P. K. Morris, A. J. Wilkins, M. J. Brown et al.
      Pages 53-56
    7. R. V. Manrique, V. Manrique
      Pages 57-63
    8. S. J. Machin, D. A. Yardumain, K. O’Flynn, D. C. Linch
      Pages 69-79
    9. J. J. F. Belch, A. Saniabadi, R. Dickson, R. D. Sturrock, C. D. Forbes
      Pages 97-102
    10. Back Matter
      Pages 103-112
  3. Cardiovascular Pharmacology, Tissue Protection and Effects on Prostaglandin Synthesis

    1. Front Matter
      Pages 113-113
    2. C. Cunard, Y. Maddox, J. Falcon, M. Ridinger, P. W. Ramwell
      Pages 115-121
    3. G. Schröder, R. Beckmann, E. Schillinger
      Pages 129-137
    4. G. Siegel, G. Stock, F. Schnalke, B. Litza
      Pages 143-149
    5. M. Haberey, O. Loge, B. Maaß, G. Ohme
      Pages 151-158
    6. K. Schrör
      Pages 159-178
    7. B. Müller, B. Maaß, C.-S. Stürzebecher, W. Witt
      Pages 195-204
    8. F. Numano, T. Koyama, K. Moriya, K. Nishiyama, K. Shimokado, Y. Kishi et al.
      Pages 231-242
    9. M. L. Foegh, J. R. Rowles, B. S. Khirabadi, P. W. Ramwell
      Pages 243-246
    10. J. Cahn, M. G. Borzeix
      Pages 247-255
    11. H. Jellinek, G. Stock, E. Takács
      Pages 269-278
    12. Back Matter
      Pages 279-286
  4. Personal Views

    1. Front Matter
      Pages 287-287
    2. G. de Gaetano
      Pages 289-291
    3. K. Schrör
      Pages 299-299
    4. J. R. Parratt
      Pages 301-303
  5. Back Matter
    Pages 305-314

About these proceedings


Ten years after the discovery of prostacyclin, our knowledge of its biochemical mode of action, pharmacological properties, pathophysiological significance and therapeutic applications is ever expanding. Prostacyclin is both complex and unique as demonstrated by its unusual feature of being chemically and meta­ bolically unstable when compared to other prostanoids and known amine or peptide mediators. Although physiologically essential, the chemical instability of prostacyclin poses a serious drawback in laboratory and clinical studies. It is one of the genuine objectives of pharmaceutical research to supply synthetic compounds which overcome the inherent drawbacks - considering investigational and therapeutic use - of endogenous compounds. Whereas metabolic instability in certain cases could be of advantage, chemical instability definitely is not. With Iloprost, a molecule has been designed which - according to all data so far available - pertains high receptor affinity, metabolic instability (clinically this equates with a fine control of Iloprost's effects) while chemical stability has been achieved. By virtue of these characteristics Iloprost can be considered as one step towards specific interaction within the arachidonic acid cascade, namely the prostacyclin receptor. The aim of the symposium was to provide a critical experimental appraisal concerning the biochemical mode of action and pharmacological properties of prostacyclin and Iloprost.


Prostaglandin arrhythmia artery atherosclerosis cardiovascular chemistry heart instability molecule myocardial infarction pharmacology platelet research resistance thromboxane

Editors and affiliations

  • R. J. Gryglewski
    • 1
  • G. Stock
    • 2
  1. 1.Department of PharmacologyCopernicus Academy of MedicineCracowPoland
  2. 2.Cardiovascular PharmacologySchering AGBerlin 65Germany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1987
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-71501-3
  • Online ISBN 978-3-642-71499-3
  • Buy this book on publisher's site